Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès, Aurélien; Jaurand, Marie-Claude; Renier, Annie; Couchy, Gabrielle; Hysi, Ilir; Elarouci, Nabila; Galateau-Sallé, Françoise; Copin, Marie-Christine; Hofman, Paul; Cazes, Aurélie; Andujar, Pascal; Imbeaud, Sandrine; Petel, Fabien; Pairon, Jean-Claude; Le Pimpec-Barthes, Francoise; Zucman-Rossi, Jessica; Jean, Didier.
Clin Cancer Res
; 20(5): 1323-34, 2014 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-24443521
Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
Prognostic value of several biomarkers for the patients with malignant pleural mesothelioma.
[Clinical Pathological Diagnosis, and Treatment for Pleural Mesothelioma].
Correlation of patient survival with clinical tumor measurements in malignant pleural mesothelioma.
Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma.
Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
About the diagnostic value of BAP-1 antibody in malignant pleural mesothelioma: a meta-analysis.
Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.